CBS 2019
CBSMD教育中心
中 文

血流储备分数

Abstract

Recommended Article

Identification of High-Risk Plaques Destined to Cause Acute Coronary Syndrome Using Coronary Computed Tomographic Angiography and Computational Fluid Dynamics The Impact of Coronary Physiology on Contemporary Clinical Decision Making Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis Prognostic Implications of Plaque Characteristics and Stenosis Severity in Patients With Coronary Artery Disease Coronary Flow Reserve in the Instantaneous Wave-Free Ratio/Fractional Flow Reserve Era: Too Valuable to Be Neglected Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial Coronary Microcirculation Downstream Non-Infarct-Related Arteries in the Subacute Phase of Myocardial Infarction: Implications for Physiology-Guided Revascularization Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation
|<< 1 2 3 4 5 6 7 8 9 >>|

Original Research

JOURNAL：CBSMD Article Link

药物涂层球囊在小血管介入中的应用

CBSMD

Pre-reading

DCB经现阶段临床试验证实在冠脉小血管狭窄干预方向与DES可一决高下，其优势在于：

1) 不改变血管解剖结构；

2) 药物涂层球囊具抗血管壁增生药物，可起到预防支架内再狭窄之目的；

3) 有证据提示DCB术后DAPT服药周期可短于DES术后；

4) DCB可为后续CABG或支架置入赢取更多可能。



将DCB应用在小血管介入领域时应持有的谨慎态度：

1）尽管现有指南尚未对DCB应用前腔内影像学IVUS，OCT的仔细评估做明确规定，但已有证据显示腔内影像学的先进性在指导DES置入或DCB时可转换为更好的预后；

2）应进一步明确DCB适应证及人群。



围绕DCB术后预后非劣效于DES预后的RCT研究包括：


2018年8月“Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial”

样本：欧洲14个介入中心758例，随机比DES (paclitaxel-eluting stent) vs. DCB 1:1

病变：<3 mm直径的冠脉病变

随访：1年

DAPT：DCB组4周，DES组non-ACS患者 6周，ACS患者1年

结论: 在一年内，所有小血管疾病(< 3mm)患者随机分配到DES组和DCB组，组间MACE一年发生率无差异，符合非劣效性标准。



2018年12月“Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial”

样本：多中心230例

病变：2.25 ≤冠脉小血管直径 ≤2.75 mm

随访：9个月和1年

结论：9个月造影随访DCB组节段狭窄直径百分比较DES组下降了10.9%，满足非劣效标准；而一年组间靶病变失败率无统计学差异。




2019年5月“Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial”

样本：单中心120例

病变：STEMI, 罪犯病变非严重钙化，预扩后残余冠脉狭窄 <50%

随访：9个月FFR随访

结论：STEMI经PPCI-DCB策略干预后，其FFR评估结果非劣效于DES策略。


更多内容详细参阅“Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review”和《紫杉醇涂层球囊的最新研究进展》。




>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top